Ernexa Therapeutics Surges 78% on Narrowed Losses and Promising Cancer Therapy Data

BTCC / BTCC Square / Global Cryptocurrency /

Author:

Release Time:

2026-05-13 04:42:02

BTCCSquare news:

Ernexa Therapeutics (ERNA) shares skyrocketed 78% following Q1 2026 results showing a reduced net loss of $5.51M, down from $8.20M year-over-year. The biotech firm's cash position strengthened to $9.2M after a $10.5M February offering.

Investors responded enthusiastically to preclinical data showing lead candidate ERNA-101 achieved complete tumor clearance when combined with PD-1 therapy. 'These survival rates in animal models suggest transformative potential,' noted one analyst.

The company executed a 1-for-25 reverse split in May while establishing a $50M shelf registration for future capital needs. Operating expenses totaled $5.6M for the quarter, with R&D accounting for $1.9M of that figure.

By:

Log in to Reply

Tech Giants and Quantum Computing Stir Market Activity

Articles on this site are sourced from public networks or curated by AI for informational purposes only and do not represent BTCC’s views. Original rights belong to the respective authors. For copyright concerns, please contact [email protected]. BTCC assumes no liability for the accuracy, timeliness, or completeness of this information, and disclaims all liability arising from reliance on such content. This content is for reference only and should not be taken as investment, legal, or commercial advice.